Even when each individual peptide appears well tolerated, the combination deserves a separate, honest discussion
Hillman D, Mitchell S, Streatfeild J, Burns C, Bruck D, Pezzullo L
NICE recommends checking lipid profiles 3 months after initiating or changing lipid-lowering therapy, then annually once stable
Ambery P, Parker VE, Stumvoll M, et al
Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis
Novo is expected to release results from its 5-year SELECT trial looking into the health impact of its injectable drug, particularly around heart disease, later this year